menu
    • menu

    Company profile for Lantern Pharma

    NEW Drugs in Dev: 9
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lantern Pharma is a clinical stage oncology biotech that leverages Artificial Intelligence and Machine Learning to deeply understand genomic data. Lantern in-licenses and develops therapies using genomic data, Machine Learning, and computational biology modeling to identify the patient groups most likely to respond to a therapy, and to clarify the potential underlying mechanism(s) of action.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lantern PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Kearny Point, Kearny, New Jersey 07032, US
    Telephone
    Telephone
    917-810-9412
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lanternpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lanternpharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lantern Pharma Gets FDA Approval for HARMONIC Phase 2 Trial
    Lantern Pharma Gets FDA Approval for HARMONIC Phase 2 Trial

    19 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-19/lantern-pharma-announces-successful-outcome-of-fda-type-c-meeting-request-for-harmonic-phase-2-tria

    PHARMIWEB
    19 May 2026
    Share Share
    Lantern Pharma's predictBBB.AI Evolves into Real-Time LQM
    Lantern Pharma's predictBBB.AI Evolves into Real-Time LQM

    29 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7247793

    FIRSTWORD PHARMA
    29 Apr 2026
    Share Share
    Lantern Pharma to Demo withZeta.ai After AACR 2026
    Lantern Pharma to Demo withZeta.ai After AACR 2026

    24 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260424944945/en/Lantern-Pharma-to-Debut-Public-Demonstration-of-withZeta.ai---A-Platform-to-Conquer-Rare-Cancers-on-April-30-Following-AACR-2026-Scientific-Debut

    BUSINESSWIRE
    24 Apr 2026
    Share Share
    Lantern Pharma's LP-300 Shows 8.3-Month Survival in Lung Cancer
    Lantern Pharma's LP-300 Shows 8.3-Month Survival in Lung Cancer

    20 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260420812445/en/Emerging-Data-for-Lantern-Pharmas-Investigational-Drug-LP-300-Demonstrates-8.3-Month-Median-Progression-Free-Survival-in-Patients-with-EGFR-L858R-Lung-Cancer-After-Targeted-Therapy-Failure-With-No-Added-Toxicity

    BUSINESSWIRE
    20 Apr 2026
    Share Share
    Lantern Pharma Debuts Zeta.Ai For Rare Cancer Drug Discovery
    Lantern Pharma Debuts Zeta.Ai For Rare Cancer Drug Discovery

    14 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-14/lantern-pharma-launches-withzetaai-the-world-s-first-multi-agentic-ai-co-scientist-for-rare-can

    PHARMIWEB
    14 Apr 2026
    Share Share
    Lantern Pharma Demos withZeta.ai Multi-Agentic Co-Scientist Apr 9
    Lantern Pharma Demos withZeta.ai Multi-Agentic Co-Scientist Apr 9

    02 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260402442512/en/Lantern-Pharma-Invites-Investors-Analysts-Shareholders-to-Experience-the-Future-of-Drug-Discovery-via-a-Live-Demo-of-withZeta.ai-the-Worlds-First-Multi-Agentic-Co-Scientist-for-Rare-Cancers-830-AM-Eastern-April-9-2026

    BUSINESSWIRE
    02 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search